Copyright
©The Author(s) 2025.
World J Gastrointest Surg. Sep 27, 2025; 17(9): 109152
Published online Sep 27, 2025. doi: 10.4240/wjgs.v17.i9.109152
Published online Sep 27, 2025. doi: 10.4240/wjgs.v17.i9.109152
Table 1 Demographic and baseline clinical characteristics of the study population
Baseline data | Control group (n = 49) | Research group (n = 50) | χ2/t | P value |
Gender, n (%) | 0.624 | 0.430 | ||
Male | 35 (71.43) | 32 (64.00) | ||
Female | 14 (28.57) | 18 (36.00) | ||
Age (years) | 53.86 ± 7.03 | 56.32 ± 9.23 | 1.490 | 0.140 |
Cirrhosis duration (years) | 3.61 ± 1.38 | 4.12 ± 1.75 | 1.608 | 0.111 |
Child-Pugh grade, n (%) | 1.974 | 0.373 | ||
A | 25 (51.02) | 20 (40.00) | ||
B | 20 (40.82) | 22 (44.00) | ||
C | 4 (8.16) | 8 (16.00) | ||
Bleeding duration (hour) | 21.16 ± 4.45 | 23.10 ± 6.45 | 1.739 | 0.085 |
Bleeding volume (mL) | 598.39 ± 70.59 | 593.50 ± 73.38 | 0.338 | 0.736 |
Table 2 Comparative analysis of treatment efficacy, n (%)
Clinical efficacy | Control group (n = 49) | Research group (n = 50) | χ2 | P value |
Markedly effective | 22 (44.90) | 28 (56.00) | ||
Effective | 15 (30.61) | 18 (36.00) | ||
Ineffective | 12 (24.49) | 4 (8.00) | ||
Total efficacy | 37 (75.51) | 46 (92.00) | 4.966 | 0.026 |
Table 3 Univariate analysis of efficacy predictors, n (%)
Factor | Ineffective group (n = 16) | Effective group (n = 83) | χ2 | P value |
Gender | 0.234 | 0.629 | ||
Male (n = 67) | 10 (62.50) | 57 (68.67) | ||
Female (n = 32) | 6 (37.50) | 26 (31.33) | ||
Age (years) | - | 0.014 | ||
< 55 (n = 47) | 3 (18.75) | 44 (53.01) | ||
≥ 55 (n = 52) | 13 (81.25) | 39 (46.99) | ||
Cirrhosis duration (years) | - | 0.013 | ||
< 4 (n = 40) | 2 (12.50) | 38 (45.78) | ||
≥ 4 (n = 59) | 14 (87.50) | 45 (54.22) | ||
Child-Pugh grade | 1.553 | 0.213 | ||
A (n = 45) | 5 (31.25) | 40 (48.19) | ||
B/C (n = 54) | 11 (68.75) | 43 (51.81) | ||
Bleeding duration (hour) | 5.634 | 0.018 | ||
< 24 (n = 63) | 6 (37.50) | 57 (68.67) | ||
≥ 24 (n = 36) | 10 (62.50) | 26 (31.33) | ||
Bleeding volume (mL) | 0.159 | 0.690 | ||
< 600 (n = 54) | 8 (50.00) | 46 (55.42) | ||
≥ 600 (n = 45) | 8 (50.00) | 37 (44.58) | ||
Treatment approach | - | 0.031 | ||
Endoscopic variceal ligation (n = 49) | 12 (75.00) | 37 (44.58) | ||
Endoscopic variceal ligation + propranolol (n = 50) | 4 (25.00) | 46 (55.42) |
Table 4 Multivariate regression analysis of efficacy predictors
Factor | β | SE | Wald | P value | OR | 95%CI |
Age (years) | 2.028 | 0.751 | 7.284 | 0.007 | 7.596 | 1.742-33.114 |
Cirrhosis duration (years) | 2.048 | 0.868 | 5.563 | 0.018 | 7.750 | 1.414-42.485 |
Bleeding duration (hour) | 1.368 | 0.662 | 4.270 | 0.039 | 3.926 | 1.073-14.366 |
Treatment approach | -1.575 | 0.701 | 5.046 | 0.025 | 0.207 | 0.052-0.818 |
- Citation: Gong DF, Cheng L. Therapeutic outcomes and predictors of efficacy for endoscopic variceal ligation plus propranolol in liver cirrhosis-related upper gastrointestinal bleeding. World J Gastrointest Surg 2025; 17(9): 109152
- URL: https://www.wjgnet.com/1948-9366/full/v17/i9/109152.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v17.i9.109152